Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: olivier benrubi who wrote (10028)	1/14/2004 11:37:28 PM
From: zeta1961	Read Replies (1) \| Respond to of 52153

Idenix...yes I did take a look Hi Olivier, Quite an impressive team! and approach...what makes them compelling for me is their use of oral, non-toxic agents with meaningful superior results(so far)...the telbivudine P2 for HBV was quite impressive...eary viral response is key... which they achieved both with telbivudine and the primate study with NM-283 for HCV...eventhough one may hear dabate that it's not necessarily the case in predicting sustained viral response...in reality, from what I hear...indeed it is indicative most of the time... consensus on Longwood Ave:)(Boston's Medical area)...is that Hepatitis, esp C, will be treated much the same as HIV...a cocktail of meds using different mechanisms...reverse RNA inhibitors, idenix has nucleosides....My overall impression is even if idenix's trials go as well as their early work, it will be used in conjunction with something else...does not at all diminish it's huge potential contribution...but just a reality check on where therapy is heading for the next decade at least.... Very well connected with an experienced board and management team...top shelf academics involved...headquartered in Cambridge,MA...my old neighborhood:)...with MIT/Harvard, Whitehead Institute access... I'm limited in my IPO experience...I know 2003 biotech IPO's have not fared well overall...Novartis has 51% ownership and it seems that they got this company at bargain basement prices...not only did idenix give over 51%, but the royalty burden was not disclosed on the website...certainly, an inexperienced investor question(s)...how much do you think they'll price the IPO?....Since Novartis is a mega, successful pharma with huge interest, is it more prudent to buy Novartis?....given the risk/reward?... I wrote several pages of notes and will pass this on to some people who will be able to give me more of an insider's view...and will post when I get a response...thank you for sharing... Zeta